The first empirical evidence to support CSCs was obtained from human acute myeloid leukemia (AML) when it was discovered that the ability to transplant AML to severe combined immune-deficient mice is restricted to leukemia cells with a CD34+/CD38− immunophenotype similar to normal hematopoietic stem cells (1). The gene discussed is CD38; the disease is acute myeloid leukemia.